Pacing and Clinical Electrophysiology · 2010 · 15 citations · 10 references
MedicineCardiologyPharmacotherapyCardiovascular PharmacotherapyClinical CardiologyClinical PharmacologyAntiarrhythmic TherapyArrhythmia PharmacotherapyAtrial FibrillationCardiac ArrhythmiasCardiac MedicationsCardiac PharmacotherapyAntiarrhythmic Drug DosingAntiarrhythmic Drug EffectsImplantable Cardioverter DefibrillatorsVentricular Arrhythmia PharmacotherapyVentricular Tachycardia Storm
The patient was a 57-year-old man with Brugada syndrome, who had been implanted with a implantable cardioverter defibrillator (ICD). The frequency of ventricular fibrillation (VF) started to increase about 4 years after ICD implantation, occurring, at worst, six times in one night. Immediately after starting oral administration of disopyramide, VF stopped occurring. He then discontinued taking disopyramide, but immediately after the discontinuation VF started occurring again, so he restarted taking disopyramide. Thereafter, VF completely stopped occurring. Findings observed in our case suggest that disopyramide could be added in our arsenal of medications for treating arrhythmic storms in patient with Brugada syndrome.
10
Hydroquinidine therapy in Brugada syndrome
Jean‐Sylvain Hermida, Isabelle Denjoy, J. Clerc et al. · Journal of the American College of Cardiology · 2004 · 270 citations
Silvio Litovsky, Charles Antzelevitch · Circulation Research · 1990 · 266 citations · Full text
Medicine, Cardiology, Pharmacology +16